SAN ANTONIO–(DWPR)–Natera, a global leader in cell-free DNA testing, announced that it will present new data from its Signatera™ test in multiple abstracts at the San Antonio Breast Cancer Symposium (SABCS). These studies highlight the clinical utility of Signatera in early-stage breast cancer, providing valuable insights into treatment monitoring and patient outcomes.

“We are excited to share the latest findings from our Signatera studies, which demonstrate the significant impact of ctDNA testing in early detection and ongoing cancer management,” said Alexey Aleshin, MD, VP of Oncology Medical Affairs at Natera.

The SABCS presentations will include key data on how Signatera enables better-informed treatment decisions, further strengthening its role as a transformative tool in oncology. Natera continues to innovate in the field of molecular diagnostics, ensuring patients and clinicians have access to advanced tools for improved care.

About Natera

Natera is a global leader in cfDNA testing, committed to delivering innovation in cancer diagnostics, women’s health, and organ health. With its Signatera test, Natera provides groundbreaking solutions that help transform the way patients are treated across multiple clinical domains. To learn more, visit natera.com.

Contacts

Natera Communications
Jane Doe
[email protected]